ASPO Abstracts

Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Recruitment feasibility for a multi-component lifestyle modification program for men on androgen deprivation therapy for prostate cancer

Authors: Algotar AM, Babiker HM, Abraham I, Dougherty S, Courneya KS, Ligibel J, Hsu C-H, Chow H-H, Marrero D, Kumar R, Ramakumar S, Hoy R, Mack C, Smith TE, Jones PA, Niemiro G, Lopez J, Thomson C

Category: Survivorship & Health Outcomes/Comparative Effectiveness Research
Conference Year: 2020

Abstract Body:
Purpose: Androgen deprivation therapy (ADT) for prostate cancer has demonstrated improved overall and disease specific mortality. However, adverse effects associated with ADT increase cardio-metabolic risk and decrease quality of life (QoL). The Diabetes Prevention Program (DPP), has demonstrated improvements in cardio- metabolic risk and QoL in women with breast cancer. We developed The Comprehensive Lifestyle Improvement Program for Prostate cancer (CLIPP) as a DPP-adapted program to 1) demonstrate feasibility of conducting a lifestyle modification intervention in men on ADT for prostate cancer and 2) demonstrate early efficacy of this lifestyle modification intervention on cardio-metabolic risk factors and QoL. This abstract presents the recruitment feasibility as well as baseline metabolic health and QoL data from the CLIPP trial. Methods: Using a single-arm, unblinded, clinical trial design, we recruited 31 men diagnosed with prostate cancer exposed to ADT in the last five years. A 16–week intervention was delivered both in-person and over the telephone; participants were followed through 24 weeks. Anthropometric measures, serum, and QoL data were collected at baseline, 12, and 24 weeks. Results: Recruitment for this feasibility study was completed in seven months and 51.7% of eligible men consented to participate. The prevalence of overweight and obesity was 73% and metabolic syndrome was 63%. Metabolic syndrome was associated with longer duration of ADT (Odds ratio and 95% confidence intervals: 1.08 (1.008-1.167)). Only 17.1% of men reported their QoL as excellent; and only 13.8% reported no fatigue or pain. The proportion of men reporting urinary concerns was 70% whereas those reporting sexual function concerns was 73.3%. Conclusion: It was feasible to recruit prostate cancer survivors on ADT to a DPP- based lifestyle modification trial. The high prevalence of metabolic disease and QoL concerns support the need for a lifestyle modification intervention to address these issues in this vulnerable population.

Keywords: Prostate Cancer Lifestyle Modification